Observations on vancomycin use in U.S. hospitals

American Journal of Health-System Pharmacy

Volumn 64, Issue 15, 2007, Pages 1633-1641

  Paladino, Joseph A ^a,b   Sunderlin, Jenna L ^c   Adelman, Martin H ^c   Singer, Mendel E ^d   Schentag, Jerome J ^b,c  

^a CPL Associates LLC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c CPL Associates   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotics; Bacterial infections; Blood levels; Data collection; Drug use; Hospitals; Methicillin; Penicillins; Pharmacists, hospital; Protocols; Resistance; Staphylococcus aureus; Toxicity; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; COTRIMOXAZOLE; LINEZOLID; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; GRAM POSITIVE BACTERIUM; HOSPITAL PHARMACY; HUMAN; INFORMATION PROCESSING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; OBSERVATIONAL STUDY; PHARMACIST; POLICY; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; TEACHING HOSPITAL; UNITED STATES;

EID: 34547416175     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060651     Document Type: Article

References (26)

1. Fridkin SK, Edwards JR, Pichette SC et al. Determinants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis. 1999; 28:1119-25.
2. Schentag JJ, Hyatt JM, Carr JR et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis. 1998; 26:1204-14.
3. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34:1481-90.
4. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005; 55:240-5.
5. Weigelt J, Kaafarani HM, Itani KM et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg. 2004; 188:760-6.
6. Rubinstein E, Cammarata S, Oliphant T et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001; 32:402-12.
7. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006; 42 (suppl 1):S3-4.
8. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993; 27:594-8.
9. Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother. 1994; 28:1397-9.
10. Tobin CM, Darville JM, Thomson AH et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for An tibiotic Assays questionnaire. J Antimicrob Chemother. 2002; 50:713-8.
11. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42(suppl 1):S35-9.
12. Darko W, Medicis JJ, Smith A et al. Mississippi Mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003; 23:643-50.
13. Rybak MJ, Albrecht LM, Boike SC et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25:679-87.
14. O'Sullivan TL, Ruffing MJ, Lamp KC et al. Prospective evaluation of red man syndrome in patients receiving vancomycin. J Infect Dis. 1993; 168:773-6.
15. Schentag JJ, Paladino JA, Birmingham MC et al. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems. J Pharm Technol. 1995; 11:203-10.
16. Rifenburg RP, Paladino JA, Hanson SC et al. Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health-Syst Pharm. 1996; 53:2054-62.
17. Bhavnani SM, Callen WA, Forrest A et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health-Syst Pharm. 2003; 60:1962-70.
18. Canaday BR, Poe TE, Sawyer WT et al. Fractional adjustment of predicted creatinine clearance in females. Am J Hosp Pharm. 1984; 41:1842-3.
19. Paladino JA, Kapfer JA, DiBona JR. Bedside estimation of creatinine clearance: which method is most accurate while least complex? Hosp Formul. 1983; 21:709-15.
20. Smith CR, Lipsky JJ, Laskin OL et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980; 302:1106-9.
21. Shah NP, Reddy P, Paladino JA et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin. 2004; 20:779-90.
22. Derouin CG. Wyandotte Hospital and Medical Center's quality management process. Patient outcomes: the new paradigm for monitoring performance. Orlando, FL: National Association for Healthcare Quality; 1992:128-41.
23. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003; 124:1789-97.
24. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925-42.
25. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.
26. Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis. 2006; 42(suppl 1):S40-50.